Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience

Kuruvilla, 2007, Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma, Biol Blood Marrow Transplant, 13, 925, 10.1016/j.bbmt.2007.04.006 Crawley, 2007, Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning, Blood, 109, 3588, 10.1182/blood-2006-07-036848 Stewart, 2007, A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, 21, 529, 10.1038/sj.leu.2404516 Lim, 2007, Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative, Bone Marrow Transplant, 41, 587, 10.1038/sj.bmt.1705937 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Bruno, 2007, A comparison of allografting with autografting for newly diagnosed myeloma, N Engl J Med, 356, 1110, 10.1056/NEJMoa065464 Garban, 2006, Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, 107, 3474, 10.1182/blood-2005-09-3869 Rosinol, 2008, A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma, Blood, 112, 3591, 10.1182/blood-2008-02-141598 Valcarcel, 2005, Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies, Eur J Haematol, 74, 144, 10.1111/j.1600-0609.2004.00360.x Chakraverty, 2010, Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution, Blood, 116, 3080, 10.1182/blood-2010-05-286856 D'Sa, 2003, Br J Haematol, 123, 309, 10.1046/j.1365-2141.2003.04612.x Maloney, 2003, Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma, Blood, 102, 3447, 10.1182/blood-2002-09-2955 Kroger, 2004, Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma, Blood, 104, 3361, 10.1182/blood-2004-05-2031 Dimopoulos, 2007, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma, N Engl J Med, 357, 2123, 10.1056/NEJMoa070594 Weber, 2007, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America, N Engl J Med, 357, 2133, 10.1056/NEJMoa070596 Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma, N Engl J Med, 352, 2487, 10.1056/NEJMoa043445